Contineum Therapeutics, Inc. SEC filings document a clinical-stage biopharmaceutical company developing oral small-molecule therapies for neuroscience, inflammation and immunology indications. The filing record covers PIPE-791 and PIPE-307 clinical disclosures, including trial data, protocol updates and Regulation FD materials tied to the company’s development programs.
Contineum’s filings also address quarterly financial results, proxy governance, board and compensation matters, Nasdaq inducement equity plans, Class A common stock registered on Nasdaq, and financing activity through shelf registration statements, underwritten offerings and sales-agreement arrangements. These documents describe the company’s capital structure, governance framework, risk-related clinical disclosures and material-event reporting.
Contineum Therapeutics, Inc. (CTNM) reported that it issued a press release with topline data from its Phase 2 PIPE-307 VISTA trial for treating relapsing-remitting multiple sclerosis. The company furnished this press release as Exhibit 99.1 to the report and incorporated it by reference, indicating that detailed clinical results are contained in that exhibit.
Contineum Therapeutics (CTNM) reported a Q3 2025 net loss of $12.8 million, driven by research and development of $11.0 million and general and administrative expense of $3.9 million. Interest income was $2.0 million, partially offsetting operating costs.
Liquidity remains strong with $182.4 million in cash, cash equivalents and marketable securities as of September 30, 2025. Management states these resources are sufficient for at least 12 months. During the quarter, the company activated its at-the-market program, selling 3,241,110 Class A shares at a weighted average price of $6.04 for $19.0 million in net proceeds.
Pipeline execution continued. PIPE-791 completed Phase 1 and Phase 1b PET work; a global Phase 2 in idiopathic pulmonary fibrosis is planned for Q4 2025, and an exploratory Phase 1b chronic pain trial began dosing in March 2025 with topline data expected in the first half of 2026. PIPE-307, partnered with J&J, has a fully enrolled Phase 2 RRMS trial with topline results targeted for Q4 2025, and J&J initiated a Phase 2 study in major depressive disorder in December 2024.
Contineum Therapeutics, Inc. furnished an 8-K to announce it issued a press release with financial results for the third quarter ended September 30, 2025. The press release is included as Exhibit 99.1.
The information under Item 2.02, including Exhibit 99.1, is being furnished and is not deemed “filed” for purposes of Section 18 of the Exchange Act, and will not be incorporated by reference into any Securities Act registration statement unless specifically identified.
Contineum Therapeutics reported that a pharmacokinetic–pharmacodynamic relationship between exposure to its investigational drug PIPE-791 and LPA1 brain receptor occupancy (RO) was confirmed in both healthy volunteers and progressive multiple sclerosis (PrMS) patients. Plasma EC50 values were 37 ng/mL at 24 hours and 12 ng/mL at 168 hours post-dose, indicating sustained target engagement after dosing. The company states its planned Phase 2 proof-of-concept doses are expected to provide >90% target coverage at trough with once-daily dosing.
The filing also contains customary forward-looking statements and risk disclosures noting that these early clinical results may not predict future outcomes and that development, regulatory, and funding risks could affect plans.
Contineum Therapeutics, Inc. Schedule 13G/A filed by Perceptive Advisors LLC, Joseph Edelman and Perceptive Life Sciences Master Fund, Ltd. reports that the Master Fund directly holds 699,486 shares of Class A common stock, representing 3.2% of the outstanding class based on 21,625,223 shares. Perceptive Advisors, as investment manager, and Mr. Edelman, as managing member, each disclose the same beneficial ownership because they may be deemed to beneficially own the Master Fund's position. The filing shows no sole voting or dispositive power and only shared voting and dispositive power for the reported shares. The filing states the position was not acquired to influence control of the issuer.
Franklin Resources, Inc., its subsidiary Franklin Advisers, Inc., and related control persons filed Amendment No. 1 to Schedule 13G for Contineum Therapeutics, Inc. (CTNM) covering Class A common stock (CUSIP 21217B100) as of 30 June 2025.
- Shares owned: 1,698,825.
- Percent of outstanding class: 8.9%.
- Voting & dispositive power: Sole power resides with Franklin Advisers; no shared power reported.
- Individuals Charles B. Johnson and Rupert H. Johnson, Jr. report 0 shares.
- The largest underlying account, Franklin Biotechnology Discovery Fund, holds 1,100,717 shares (5.8%).
- Filers certify the stake is held in the ordinary course of business with no intent to influence control.
No financial results, transactions, or additional corporate events are disclosed in this filing.
Form 4 Overview: On 06/26/2025, Contineum Therapeutics (CTNM) filed a Form 4 reporting that non-employee director Sarah Boyce received a stock option grant for 14,750 shares of the company’s Class A common stock at an exercise price of $4.01 per share. The option was issued under the company’s 2024 Equity Incentive Plan as part of the regular non-employee director compensation program.
Key Terms: The option vests in full on the earlier of (i) June 26, 2026 (one-year anniversary of the grant) or (ii) the next regular annual meeting of stockholders, provided Ms. Boyce remains a board member. It expires on 06/25/2035.
Post-Transaction Holdings: Following this transaction, Ms. Boyce beneficially owns 14,750 derivative securities (stock options) directly.
Investor Takeaway: The filing reflects routine director compensation and signals alignment of director incentives with shareholder value; financial impact and dilution are immaterial relative to typical public company share counts.
Contineum Therapeutics, Inc. (CTNM) – Form 4 insider filing
On 26 June 2025, non-employee director Evert B. Schimmelpennink received a routine annual stock-option grant under the company’s 2024 Equity Incentive Plan. The award covers 14,750 shares of Class A Common Stock with an exercise price of $4.01 and expires on 25 June 2035. The option vests in full on the earlier of 26 June 2026 or the next regular annual shareholder meeting, contingent upon continuous board service.
The filing reports no open-market purchase or sale of shares; it solely reflects a compensatory grant made pursuant to the Board’s non-employee director compensation program. Following the grant, the director beneficially owns 14,750 derivative securities directly. No other transactions or changes in ownership were disclosed.
Because the transaction is part of a pre-established compensation policy and involves a small percentage of outstanding shares, it is unlikely to have a material impact on the company’s capital structure or near-term valuation.